Thermo Fisher Scientific has announced plans to invest $35m in a new pharma services supply chain facility in Germany.

The plans are aimed at expanding the company’s presence in the European Union in response to a growing demand for global clinical supply services.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thermo Fisher will use the latest technology and infrastructure to increase its European capacity for cold and ambient clinical trial materials. The new facility is slated to create more than 200 new jobs.

The facility will be scalable for mixed-use space and will offer a strategic logistical location for shipping either by road or air.

Construction of the 8,000m² facility is expected to start in the fourth quarter of this year, with building predicted to take 12 to 18 months.

"By creating a best-in-class supply chain facility in the EU, we open new opportunities to support client and patient need."

The investment will also include the option for additional expansion with the potential for doubling in size.

Fisher Clinical Services Europe vice-president and general manager Astrid Frank said: “This is an exciting time for our business, and it reinforces our commitment to best serve our clients globally.

“By creating a best-in-class supply chain facility in the EU, we open new opportunities to support client and patient need.”

The new facility will comply with GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019.

It will join Thermo Fisher’s 20 purpose-built cGMP facilities worldwide.